Ocular delivery of cyclosporine A based on glyceryl monooleate/poloxamer 407 liquid crystalline nanoparticles: Preparation, characterization, in vitro corneal penetration and ocular irritation

Journal of Drug Targeting

Volumn 20, Issue 10, 2012, Pages 856-863

  Chen, Yan ^a   Lu, Yi ^b   Zhong, Yanqiang ^a   Wang, Qingping ^c   Wu, Wei ^b   Gao, Shen ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

corneal permeability; Cyclosporine A; in vitro; liquid crystalline nanoparticles; ocular drug delivery; ocular irritation

Indexed keywords

CYCLOSPORIN A; FLUORESCEIN ISOTHIOCYANATE; GLYCEROL OLEATE; NANOPARTICLE; POLOXAMER;

ANIMAL TISSUE; ARTICLE; CORNEA; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG PENETRATION; DRUG RETENTION; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG TRANSPORT; EYE IRRITATION; IN VITRO STUDY; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RABBIT; TRANSMISSION ELECTRON MICROSCOPY; X RAY DIFFRACTION;

ANIMALS; CORNEA; CYCLOSPORINE; DRUG ADMINISTRATION ROUTES; IRRITANTS; MICROSCOPY, ATOMIC FORCE; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; POLOXAMER; RABBITS;

EID: 84868383649     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2012.723214     Document Type: Article

References (39)

1. Abdulrazik M, Tamilvanan S, Khoury K, Benita S. (2001). Ocular delivery of cyclosporin A II. Effect of submicron emulsion's surface charge on ocular distribution of topical cyclosporin A. STP Pharma Sci, 11, 427-432. (Pubitemid 34016288)
2. Aksungur P, Demirbilek M, Denkbas EB, Vandervoort J, Ludwig A, Unlü N. (2011). Development and characterization of Cyclosporine A loaded nanoparticles for ocular drug delivery: Cellular toxicity, uptake, and kinetic studies. J Control Release, 151, 286-294.
3. Barauskas J, Johnsson M, Tiberg F. (2005). Self-assembled lipid superstructures: Beyond vesicles and liposomes. Nano Lett, 5, 1615-1619. (Pubitemid 41251697)
4. Basaran E, Demirel M, Sirmag B, Yazan Y. (2010). Cyclosporine-A incorporated cationic solid lipid nanoparticles for ocular delivery. J Microencapsul, 27, 37-47.
5. BenEzra D, Maftzir G. (1990). Ocular penetration of cyclosporin A. The rabbit eye. Invest Ophthalmol Vis Sci, 31, 1362-1366. (Pubitemid 20212368)
6. Calvo P, Thomas C, Alonso MJ, Vilajato JL, Robinson Jr. (1994). Study of the mechanism of interaction of poly(?-caprolactone) nanocapsules with the cornea by confocal laser scanning microscopy. Int J Pharm, 103, 283-291.
7. De Campos AM, schez A, Alonso MJ. (2001). Chitosan nanoparticles: A new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A. Int J Pharm, 224, 159-168. (Pubitemid 32706495)
8. Dey S, Mitra AK. (2005). Transporters and receptors in ocular drug delivery: Opportunities and challenges. Expert Opin Drug Deliv, 2, 201-204. (Pubitemid 41130877)
9. Di Venosa G, Hermida L, Batlle A, Fukuda H, Defain MV, Mamone L, Rodriguez L, MacRobert A, Casas A. (2008). Characterisation of liposomes containing aminolevulinic acid and derived esters. J Photochem Photobiol B, Biol, 92, 1-9. (Pubitemid 351944030)
10. el-Asrar AM, Tabbara KF, Geboes K, Missotten L, Desmet V. (1996). An immunohistochemical study of topical cyclosporine in vernal keratoconjunctivitis. Am J Ophthalmol, 121, 156-161. (Pubitemid 26055159)
11. el Tayar N, Mark AE, Vallat P, Brunne RM, Testa B, van Gunsteren WF. (1993). Solvent-dependent conformation and hydrogen-bonding capacity of cyclosporin A: Evidence from partition coefficients and molecular dynamics simulations. J Med Chem, 36, 3757-3764. (Pubitemid 24006703)
12. Esposito E, Cortesi R, Drechsler M, Paccamiccio L, Mariani P, Contado C, Stellin E, Menegatti E, Bonina F, Puglia C. (2005). Cubosome dispersions as delivery systems for percutaneous administration of indomethacin. Pharm Res, 22, 2163-2173. (Pubitemid 41821596)
13. Gan L, Han S, Shen J, Zhu J, Zhu C, Zhang X, Gan Y. (2010). Selfassembled liquid crystalline nanoparticles as a novel ophthalmic delivery system for dexamethasone: Improving preocular retention and ocular bioavailability. Int J Pharm, 396, 179-187.
14. Ganesan V, Milford DV, Taylor CM, Hulton SA, Parvaresh S, Ramani P. (2002). Cyclosporin-related nephrotoxicity in children with nephrotic syndrome. Pediatr Nephrol, 17, 225-6; author reply 227. (Pubitemid 36076042)
15. Garg G, Saraf S, Saraf S. (2007). Cubosomes: An overview. Biol Pharm Bull, 30, 350-353.
16. Giorgione JR, Huang Z, Epand RM. (1998). Increased activation of protein kinase C with cubic phase lipid compared with liposomes. Biochemistry, 37, 2384-2392. (Pubitemid 28119313)
17. G̈ EH, Sandri G, Egrilmez S, Bonferoni MC, geri T, Caramella C. (2009). Cyclosporine a-loaded solid lipid nanoparticles: Ocular tolerance and in vivo drug release in rabbit eyes. Curr Eye Res, 34, 996-1003.
18. Guan P, Lu Y, Qi J, Niu M, Lian R, Hu F, Wu W. (2011). Enhanced oral bioavailability of cyclosporine A by liposomes containing a bile salt. Int J Nanomedicine, 6, 965-974.
19. Han S, Shen JQ, Gan Y, Geng HM, Zhang XX, Zhu CL, Gan L. (2010). Novel vehicle based on cubosomes for ophthalmic delivery of flurbiprofen with low irritancy and high bioavailability. Acta Pharmacol Sin, 31, 990-998.
20. Kachi S, Hirano K, Takesue Y, Miura M. (2000). Unusual corneal deposit after the topical use of cyclosporine as eyedrops. Am J Ophthalmol, 130, 667-669.
21. Kanai A, Alba RM, Takano T, Kobayashi C, Nakajima A, Kurihara K, Yokoyama T, Fukami M. (1989). The effect on the cornea of alpha cyclodextrin vehicle for cyclosporin eye drops. Transplant Proc, 21, 3150-3152. (Pubitemid 19124695)
22. Kaur IP, Smitha R. (2002). Penetration enhancers and ocular bioadhesives: Two new avenues for ophthalmic drug delivery. Drug Dev Ind Pharm, 28, 353-369. (Pubitemid 34547874)
23. Koevary SB. (2003). Pharmacokinetics of topical ocular drug delivery: Potential uses for the treatment of diseases of the posterior segment and beyond. Curr Drug Metab, 4, 213-222. (Pubitemid 36656479)
24. Kuwano M, Ibuki H, Morikawa N, Ota A, Kawashima Y. (2002). Cyclosporine A formulation affects its ocular distribution in rabbits. Pharm Res, 19, 108-111. (Pubitemid 34075115)
25. Lai J, Chen J, Lu Y, Sun J, Hu F, Yin Z, Wu W. (2009). Glyceryl monooleate/poloxamer 407 cubic nanoparticles as oral drug delivery systems: I. In vitro evaluation and enhanced oral bioavailability of the poorly water-soluble drug simvastatin. AAPS PharmSciTech, 10, 960-966.
26. Lai J, Lu Y, Yin Z, Hu F, Wu W. (2010). Pharmacokinetics and enhanced oral bioavailability in beagle dogs of cyclosporine A encapsulated in glyceryl monooleate/poloxamer 407 cubic nanoparticles. Int J Nanomedicine, 5, 13-23.
27. Lallemand F, Felt-Baeyens O, Besseghir K, Behar-Cohen F, Gurny R. (2003). Cyclosporine A delivery to the eye: A pharmaceutical challenge. Eur J Pharm Biopharm, 56, 307-318. (Pubitemid 37346503)
28. Lang JC. (1995). Ocular drug-delivery conventional ocular formulations. Adv Drug Deliver Rev, 16, 39-43.
29. Larsson K. (1989). Cubic lipid-water phases: Structures and biomembrane aspects. J Phys Chem, 93, 7304-7314.
30. Mannermaa E, Vellonen KS, Urtti A. (2006). Drug transport in corneal epithelium and blood-retina barrier: Emerging role of transporters in ocular pharmacokinetics. Adv Drug Deliv Rev, 58, 1136-1163.
31. Mihatsch MJ, Kyo M, Morozumi K, Yamaguchi Y, Nickeleit V, Ryffel B. (1998). The side-effects of ciclosporine-A and tacrolimus. Clin Nephrol, 49, 356-363. (Pubitemid 28271466)
32. Milani JK, Pleyer U, Dukes A, Chou HJ, Lutz S, rkert D, Schmidt KH, Mondino BJ. (1993). Prolongation of corneal allograft survival with liposome-encapsulated cyclosporine in the rat eye. Ophthalmology, 100, 890-896. (Pubitemid 23163500)
33. Mithani SD, Bakatselou V, TenHoor CN, Dressman JB. (1996). Estimation of the increase in solubility of drugs as a function of bile salt concentration. Pharm Res, 13, 163-167. (Pubitemid 26076314)
34. Ogiso T, Iwaki M, Paku T. (1995). Effect of various enhancers on transdermal penetration of indomethacin and urea, and relationship between penetration parameters and enhancement factors. J Pharm Sci, 84, 482-488.
35. Olivero DK, Davidson MG, English RV, Nasisse MP, Jamieson VE, Gerig TM. (1991). Clinical evaluation of 1% cyclosporine for topical treatment of keratoconjunctivitis sicca in dogs. J Am Vet Med Assoc, 199, 1039-1042.
36. Sall K, Stevenson OD, Mundorf TK, Reis BL. (2000). Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology, 107, 631-639. (Pubitemid 30191329)
37. Suhonen P, jvinen T, Koivisto S, Urtti A. (1998). Different effects of pH on the permeation of pilocarpine and pilocarpine prodrugs across the isolated rabbit cornea. Eur J Pharm Sci, 6, 169-176. (Pubitemid 28473217)
38. Williams DL. (1997). A comparative approach to topical cyclosporine therapy. Eye (Lond), 11 (Pt 4), 453-464. (Pubitemid 27434976)
39. Yang D, Armitage B, Marder SR. (2004). Cubic liquid-crystalline nanoparticles. Angew Chem Int Ed Engl, 43, 4402-4409. (Pubitemid 39268845)